Tudor Investment Corp
JNCE

Tudor Investment Corp’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Tudor Investment Corp’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,160,841
Closed -$5.85M – 3081
2023
Q1 		$5.85M Buy
+3,160,841
New +$3.92M 0.09% 310
2017
Q2 		– Sell
-100,000
Closed -$2.2M – 1454
2017
Q1 		$2.2M Buy
+100,000
New +$2.12M 0.07% 180

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Tudor Investment Corp's JNCE Position: Q2 2023 in Review

Tudor Investment Corp sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,160,841 shares — an estimated $5.85M sold.

Tudor Investment Corp first reported a position in JNCE in Q1 2017 and held it in 2 quarters. The position peaked at $5.85M in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Tudor Investment Corp reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tudor Investment Corp sold 3,160,841 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.85M.
  • Tudor Investment Corp first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Tudor Investment Corp's Jounce Therapeutics, Inc. Common Stock position peaked at $5.85M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.